Toxicity Management: Development of a Novel and Immune-Mediated Adverse Events Algorithm .
Novel immunotherapy and biologic agents are being developed with the potential to improve outcomes and reduce long-term toxicities among individuals with hematologic malignancies. These emerging drugs affect neoplastic cells and the surrounding microenvironment, causing unique immune-mediated toxicities. .



The aim was to develop an algorithm for clinical staff to manage unique toxicities associated with next-generation immunotherapies indicated in the hematologic population, using a system-focused approach. .



Data were collected using specific toxicities based on the four major novel biologic classes. Immune-mediated adverse events were reported across studies. Based on published literature, institutional experience, and group consensus, a novel algorithm for managing immune-mediated toxicities was created. .



The development of this treatment algorithm provides a more streamlined approach for managing common but unique toxicities and improves safety, compliance, patient outcome, and quality of life with novel immuno-oncologic agents.
University of Texas MD Anderson Cancer Center.
Haleigh
H
Mistry
University of Texas MD Anderson Cancer Center.
Sheryl G
SG
Forbes
University of Texas MD Anderson Cancer Center.
Nathan
N
Fowler
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000465:Algorithms; D000911:Antibodies, Monoclonal / Q000633:toxicity*; D064420:Drug-Related Side Effects and Adverse Reactions / Q000209:etiology / Q000451:nursing*; D004509:Education, Nursing, Continuing; D005260:Female; D019337:Hematologic Neoplasms / Q000188:drug therapy* / Q000276:immunology* / Q000451:nursing; D006801:Humans; D007167:Immunotherapy / Q000009:adverse effects* / Q000451:nursing*; D008297:Male; D008875:Middle Aged; D009859:Oncology Nursing / Q000592:standards*; D017410:Practice Guidelines as Topic
D000911:Antibodies, Monoclonal
adverse events ; immune-mediated; immunotherapy; novel agents; toxicities